COVID-19 Archives - American College of Apothecaries

ACA WEBINAR: Methylene Blue and Clinical Opportunities

Terry Bondurant2025-09-05T11:48:22-05:00June 25th, 2025|Categories: Alzheimer's Disease, Alzheimers/Dementia, Clinical Research, compounding, Continuing Education, COVID-19, Patient Counseling, Pharmacology|Tags: ACA Fellows, ACA members, news, Pharmacists, Pharmacy Technicians, Student Pharmacists|

Wednesday, November 19, 2025
1:00 pm EASTERN / 12:00 pm CENTRAL / 11:00 am MOUNTAIN / 10:00 am PACIFIC

Curious about the latest research and clinical uses of Methylene Blue? This upcoming program will explore its emerging role in treating conditions like Lyme disease, dementia, Alzheimer’s, post-COVID syndrome, and more—plus offer practical compounding tips for pharmacy teams.

This talk aims to illuminate the evolving landscape of Methylene Blue’s applications in healthcare, specifically focusing on its novelutilization for enhancing patient outcomes. Delving into recent advancements and promising research for specific conditions such as Lyme disease, dementia, bladder health, Alzheimer’s disease, post-COVID syndrome, and for anti-aging /nootropic effects.

The program will also cover Methylene Blue’s pharmacology, including mechanisms of action, pharmacokinetics, and pharmacodynamics, helping learners describe these key concepts in detail. In addition, participants will outline evidence-based prescribing protocols and dosing strategies for Methylene Blue in clinical practice. They will learn to recognize common adverse reactions and explain appropriate management strategies to ensure patient safety.

Pharmacists can expect to gain insights into how this versatile compound is contributing to improved patient care, paving theway for a more nuanced understanding of its potential impact on healthcare outcomes. Included with be practical compounding pharmacy process tips that will benefit Pharmacy Technicians and improve lab efficiency.

Learning Objectives for Pharmacists and Pharmacy Technicians:

Describe recent advancements and research findings on methylene blue’s effectiveness in managing conditions such as Lyme disease, dementia, bladder health, Alzheimer’s disease, and COVID-19.
Recognize the potential anti-aging and nootropic effects of methylene blue and their relationship to cognitive health.
Outline the pharmacological profile of methylene blue, including mechanisms of action, pharmacokinetics, and pharmacodynamics.
List key prescribing considerations and general dosing strategies for methylene blue in clinical settings.
Identify common adverse reactions to methylene blue and recall strategies for promoting patient safety.
Identify practical tips and techniques for working with methylene blue in a compounding lab setting that support efficient workflow.

ACA Members $40; Non-Members $50

SPECIAL PRICING FOR PHARMACY TECHNICIANS AND STUDENT PHARMACISTS

CLICK HERE TO VIEW FULL ACTIVITY DESCRIPTION

Whether you’re interested in understanding the science behind Methylene Blue or want to stay current on new clinical opportunities, this session offers timely insight for pharmacists and pharmacy technicians.

The American College of Apothecaries (ACA) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACA has accredited this knowledge-based program for 1 contact hour (0.1 CEUs) of continuing education credit for pharmacists and pharmacy technicians.

ACA WEBINAR: MEN AND COVID SEVERITY – New Research that Links Them … What Are the Implications?

Taisha Cunningham2025-06-19T13:33:10-05:00June 19th, 2025|Categories: Clinical Research, Continuing Education, COVID-19, Endocrinology, Hormones, Infectious Diseases, Men's Health, Patient Counseling, Pharmacology, Public/Community Health|Tags: ACA Fellows, ACA members, news, Pharmacists, Pharmacy Technicians, Student Pharmacists|

Earn 1.0 hour (0.1 CEUs) of continuing education credit when you purchase the webinar, MEN AND COVID SEVERITY – New Research that Links Them … What Are the Implications?

This activity explores recent research highlighting the hormonal differences that may contribute to why men experienced more severe outcomes from COVID-19 compared to women. Participants will examine the role of testosterone in immune response and how its levels—and conversion to other hormones like estradiol—may have influenced COVID-19 severity in male patients. The session will also address how this hormonal imbalance might relate to other acute viral illnesses beyond COVID-19, offering broader clinical insight.

In addition, the activity will cover current evidence on testosterone therapy and its impact on cardiovascular health and prostate cancer risk, including discussion of ongoing large-scale studies such as the TRAVERSE trial. Participants will review the physiological role of dihydrotestosterone (DHT), testosterone’s more potent metabolite, and how understanding these hormonal mechanisms can help guide discussions around men’s health.

By the end of the activity, pharmacists and pharmacy technicians will be better equipped to evaluate emerging literature, understand the implications of hormone-related research, and communicate effectively with both patients and healthcare providers. This knowledge will enhance their ability to engage in meaningful conversations about hormone therapy, risks and benefits, and personalized care approaches related to testosterone and viral disease outcomes.

CLICK HERE TO VIEW FULL ACTIVITY DESCRIPTION

Whether you’re interested in understanding the science behind COVID-19 severity in men or want to stay current on hormone-related health risks, this session offers timely, research-based insight for pharmacists and pharmacy technicians. Registration is below.

The American College of Apothecaries (ACA) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACA has accredited this knowledge-based program for 1 contact hour (0.1 CEUs) of continuing education credit for pharmacists and pharmacy technicians.

Men and COVID Severity—New Research That Links Them. What Are the Implications?

Taisha Cunningham2023-01-05T09:40:33-06:00September 27th, 2022|Categories: COVID-19, Pharmacist Training, Pharmacy Technician, Risk Management|Tags: education, pharmacist, Pharmacy Technician|

Pharmacists/Technicians will have better understanding of why men suffered more severely from COVID-19 than women, and what that can mean in other acute, viral conditions. Pharmacist will be better equipped to discuss relative health risks/benefits of testosterone in cardiovascular disease and prostate cancer. Thus, the pharmacist/technician will be able to engage with and educate both physicians and patients on the information discussed regarding testosterone.

NOW AVAILABLE ON DEMAND!

Webinar Attendee: FREE
ACA & ACVP Members: $20
Non-Members: $35

Learning Objectives :

Describe medical literature linking low Testosterone in men with severity of Covid-19.
Discuss why low testosterone exerts this effect in men with Covid-19.
Describe the latest literature discussing testosterone in relationship to cardiovascular disease and prostate cancer.
Choose useful ways to find current medical literature on testosterone.

Register for On-Demand Webinar here: https://www.lecturepanda.com/a/testosterone

Bruce Biundo, RPh, B.S, FACA, joined PCCA as a pharmacy consultant in 1997 after many years as a community pharmacist. What is likely the first educational event on low testosterone in men was presented by Bruce at the PCCA International Seminar in April 1999. In a short time, the interest grew and over the intervening years, the breadth and depth of information has greatly increased. As Bruce’s knowledge increased, so did PCCA’s ability to educate pharmacists and physicians on how to diagnose and treat low testosterone in men. Over the years, Bruce has had a dozen articles published, mostly dealing with men’s health and testosterone topics. In addition, he was a contributor to Remington: The Science and Practice of Pharmacy, 22nd Edition, and is the co-author of the chapter on Nutrition in the book Aging Men’s Health. Bruce retired from PCCA in December 2021 but continues to provide compounding education.

Pharmacy Organizations Welcome FDA Authorization of COVID Vaccine: “We Stand Ready to Serve”

Terry Bondurant2020-12-12T06:53:25-06:00December 11th, 2020|Categories: COVID-19, Immunizations, News Release|Tags: COVID-19, immunizations, vaccines|

WASHINGTON, D.C. — The leaders of 18 pharmacy organizations today issued the following statement following the Food and Drug Administration’s approval of the first Emergency Use Authorization for the COVID-19 vaccine.

“We heartily welcome the decision by the U.S. Food and Drug Administration (FDA) to authorize the emergency use of the first COVID-19 vaccine, following the recommendation of the Vaccines and Related Biological Products Advisory Committee (VRBPAC).

“This is a historic moment in the nation’s effort to end the pandemic. The pharmacy profession is ready to do its part as qualified, active participants in administering these vaccines in accordance with guidance issued by the FDA, CDC, HHS and state and local health departments, as well as increasing access for the American public to these important disease prevention tools.

“We are confident that FDA has taken extraordinary care to ensure that the vaccine is safe and effective. The American people should have great confidence in the vaccine. The vast majority of pharmacists have indicated in recent surveys that they intend to be vaccinated themselves and plan to recommend the vaccine to their patients. More than 360,000 pharmacists, student pharmacists and pharmacy technicians nationwide are trained to administer vaccines.

“Pharmacists are the most accessible health care providers in the nation, with 90% of Americans living within 5 miles of pharmacy. Across the nation they stand ready, in all patient care settings, to administer the vaccine and counsel patients through this critical moment in our nation’s history. As trusted health professionals dedicated to serving the health care needs of our communities, we stand ready to serve.”

Supporting organizations
Academy of Managed Care Pharmacy
Accreditation Council for Pharmacy Education
American Association of Colleges of Pharmacy
American College of Apothecaries
American College of Clinical Pharmacy
American Pharmacists Association
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
College of Psychiatric and Neurologic Pharmacists
Hematology/Oncology Pharmacy Association
National Alliance of State Pharmacy Associations
National Association of Boards of Pharmacy
National Association of Chain Drug Stores
National Association of Specialty Pharmacy
National Community Pharmacists Association
National Pharmaceutical Association
Society of Infectious Diseases Pharmacists
Pharmacy Quality Alliance

Pharmacy Profession asked to help recruit volunteers to participate in COVID-19 vaccine clinical trials

Dana2020-09-02T14:11:51-05:00August 28th, 2020|Categories: COVID-19, Public/Community Health|

The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health (NIH) to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2.

The network is seeking the assistance of pharmacists and pharmacy personnel to inform the public of the opportunity to participate in the clinical trials. More information and the link to volunteer can be found at the COVID-19 Prevent Network website.

There are materials available to pharmacists that can be used to share with patients, communities, family and friends. A special referral code (RXRX) has been created for individuals to include when signing up that identifies pharmacy as the source of referral and demonstrate pharmacy’s impact.

The development and release of effective vaccines against COVID-19 is dependent upon recruiting sufficient numbers of individuals to participate in the vaccine clinical trials, especially individuals within these targeted demographics:

People with underlying medical conditions
People with greater chances of exposure at their job
People who live or work in elder-care facilities
People over age 65
People who work in jails or prisons
People from racial and ethnic groups that have been impacted in greater numbers by the epidemic, such as African Americans, Latinx, and Native Americans

Individuals interested in volunteering complete a short online survey that includes some personal questions and entry into a registry. The purpose of the screening registry is to create a list of potential volunteers who want to take part in current or future COVID-19 prevention clinical trials. Individuals must be 18 years or older to participate. Participation is voluntary.

COVID-19 prevention study participants will be compensated for their time. COVID-19 prevention study participants CANNOT get infected with SARS-CoV-2 or get COVID-19 illness from the study vaccine.

FAQ: https://www.coronaviruspreventionnetwork.org/clinical-studies-faq/

11″x 17″ Posters

English Poster Large Circles

English Poster Small Images

8.5″ x 11″ Flyers

English Flyer Large Circle

Spanish Flyer Large Circles

English Flyer Small Images

Spanish Flyer Small Images